BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28

• Sanofi Delivers 2017 Business EPS in Line With Guidance

  Fourth-quarter and 2017 accounts reflect the acquisition of the former Boehringer Ingelheim CHC business and the disposal of the Animal Health business.

  February 7, 2018

   · 

  12 min read
• Business

  UNITY Biotech Adds Accomplished R&D Leader David L. Lacey, M.D., to Board of Directors

  Dr. Lacey brings to UNITY more than 30 years of experience in medical research, including a 17-year tenure at Amgen leading research across multiple disease areas.

  February 7, 2018

   · 

  2 min read
• Business

  Lundbeck Delivers Its Best Financial Results Following 10% Revenue Growth and 117% Growth in Net Profit

  Revenue reached DKK 17,234 million in 2017 representing an increase of 10% (12% in local currencies) compared to 2016 .

  February 7, 2018

   · 

  2 min read
• Biotech Bay

  Exelixis Announces Updated Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Genitourinary (GU) Tumors

  The primary endpoint of the trial is to determine the dose-limiting toxicity and recommended phase 2 doses of the doublet and triplet combinations.

  February 7, 2018

   · 

  17 min read
• Pharm Country

  World’s First Single-Port Prostatectomy Using Titan Medical’s SPORT Surgical System Completed in a Preclinical Setting

  The procedure is part of the feasibility and validation studies intended to support submissions to regulators in both the United States and European Union.

  February 7, 2018

   · 

  5 min read
• Business

  Titan Medical to Host Business Update Conference Call on February 6, 2018

  To access the conference call, the dial-in numbers are (866) 595-8403 (U.S. and Canada toll free), and (706) 758-9979 (International).

  February 7, 2018

   · 

  2 min read
• Drug Development

  Xcovery Announces Initiation of Phase II Clinical Trial for Ensartinib in Melanoma Patients with ALK Alternations

  The trial is being conducted by the renowned Memorial Sloan Kettering Cancer Center (MSK) and led by MSK’s Dr. Alexander Shoushtari.

  February 7, 2018

   · 

  3 min read
• Business

  Palatin Technologies to Report Second Quarter Fiscal Year 2018 Results; Teleconference and Webcast to be held on February 12, 2018

  Palatin Technologies will announce its second quarter, fiscal year 2018 operating results on Monday, February 12, 2018 before the open of the U.S. financial markets.

  February 7, 2018

   · 

  1 min read
• Genetown

  Syros Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

  Syros today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 628,272 shares at the public offering price of $9.55 per share.

  February 7, 2018

   · 

  4 min read
• 

  Cancer Biotech Novocure Scores New $150M Debt Financing

  The cash will be used to to execute core strategies of driving commercial adoption of Optune and advancing the clinical pipeline.

  February 7, 2018

   · 

  3 min read